Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2013, Article ID 389390, 7 pages
http://dx.doi.org/10.1155/2013/389390
Research Article

Exploring the Relationship between the Inhibition Selectivity and the Apoptosis of Roscovitine-Treated Cancer Cells

1College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China
2Medical Experiment and Test Center, Capital Medical University, Beijing 100069, China

Received 22 February 2013; Accepted 18 March 2013

Academic Editor: Shuang-Qing Zhang

Copyright © 2013 Chunying Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Węsierska-Gądek, D. Gritsch, N. Zulehner, O. Komina, and M. Maurer, “Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human er-positive breast cancer cells,” Journal of Cellular Biochemistry, vol. 112, no. 3, pp. 761–772, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. O. P. Mgbonyebi, J. Russo, and I. H. Russo, “Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells,” Cancer Research, vol. 59, no. 8, pp. 1903–1910, 1999. View at Google Scholar · View at Scopus
  3. J. Węsierska-Gądek, A. Borza, O. Komina, and M. Maurer, “Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bifunctionality increases its therapeutic potential,” Acta Biochimica Polonica, vol. 56, no. 3, pp. 495–501, 2009. View at Google Scholar · View at Scopus
  4. S. J. McClue, D. Blake, R. Clarke et al., “In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine),” International Journal of Cancer, vol. 102, no. 5, pp. 463–468, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Węsierska-Gądek, A. Borza, E. Walzi et al., “Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment,” Journal of Cellular Biochemistry, vol. 106, no. 5, pp. 937–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Yarotskyy and K. S. Elmslie, “Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 2, pp. 463–472, 2012. View at Publisher · View at Google Scholar
  7. C. Le Tourneau, S. Faivre, V. Laurence et al., “Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies,” European Journal of Cancer, vol. 46, no. 18, pp. 3243–3250, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Gallorini, A. Cataldi, and V. di Giacomo, “Cyclin-dependent kinase modulators and cancer therapy,” BioDrugs, vol. 26, no. 6, pp. 377–391, 2012. View at Publisher · View at Google Scholar
  9. J. Vesely, L. Havlicek, M. Strnad et al., “Inhibition of cyclin-dependent kinases by purine analogues,” European Journal of Biochemistry, vol. 224, no. 2, pp. 771–786, 1994. View at Google Scholar · View at Scopus
  10. T. David-Pfeuty, “Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells,” Oncogene, vol. 18, no. 52, pp. 7409–7422, 1999. View at Google Scholar · View at Scopus
  11. L. Meijer, A. Borgne, O. Mulner et al., “Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5,” European Journal of Biochemistry, vol. 243, no. 1-2, pp. 527–536, 1997. View at Google Scholar · View at Scopus
  12. N. Raje, S. Kumar, T. Hideshima et al., “Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma,” Blood, vol. 106, no. 3, pp. 1042–1047, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. O. M. Tirado, S. Mateo-Lozano, and V. Notario, “Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo,” Cancer Research, vol. 65, no. 20, pp. 9320–9327, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Mihara, S. Shintani, A. Kiyota, T. Matsumura, and D. T. Wong, “Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells,” International Journal of Oncology, vol. 21, no. 1, pp. 95–101, 2002. View at Google Scholar · View at Scopus